How Losing Tiny Blood Vessel Cells Drives Brain Injury

Summary

Deep inside our brains, tiny cells called pericytes wrap around our blood vessels. They act as microscopic regulators, keeping blood flow steady and maintaining the blood-brain barrier, a strict security system that prevents harmful substances from leaking into brain tissue. To understand exactly what happens when these crucial cells disappear, researchers used a genetic technique to selectively remove brain pericytes in an animal model. They found that different types of pericytes along the blood vessel network have their own unique vulnerabilities when depleted.

When the brain experiences a moderate loss of pericytes, a cascade of temporary but serious problems begins. Blood flow drops, and the blood-brain barrier becomes abnormally permeable. Without pericytes to keep them in check, the cells lining the smallest blood vessels, known as capillary endothelial cells, undergo a radical change. They reprogram themselves into an activated, inflamed state. During this transformation, they increase production of a protein called VCAM-1 while reducing expression of MFSD2A, a crucial transporter protein.

This molecular reprogramming acts as a trigger for wider brain damage, specifically harming the heavily insulated wiring of the brain known as white matter. Researchers compared their findings across different species to see how this translates to human health. They discovered that the genetic changes seen in the altered animal blood vessels closely match the gene signatures found in humans suffering from small vessel disease.

Why it matters.

Small vessel disease is a major culprit behind cognitive decline and neurovascular issues in human patients. By pinpointing pericyte loss as a root cause of blood vessel inflammation and white matter injury, scientists now have a clearer map of how this destructive process begins. This research reveals that blood vessels do not just passively degenerate. Instead, the loss of pericytes actively forces the vessel lining to change its behavior and become harmful to the surrounding brain tissue.

For the future of medicine, these findings point to potential new targets for drug development. If therapies can be designed to protect pericytes or block the harmful reprogramming of the blood vessel lining, it might be possible to halt the progression of small vessel disease early on. However, researchers caution that these discoveries are based on early-stage preclinical animal models. Direct clinical confirmation in human patients will be absolutely necessary before these insights can be turned into new medical treatments.

From the source

The story in numbers.

Inducible genetic driver used for pericyte ablation: Atp13a5
Interferon signalling pathway activated by pericyte depletion: Type I

Keep the context

Follow the evidence.

This source is a preprint and has not completed peer review. Its findings are provisional.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

How Losing Tiny Blood Vessel Cells Drives Brain Injury

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.